Apeiron Therapeutics Sells 50% Rights to CDK7 Inhibitor GTAEXS617 to Exscientia for Over $100M Potential Deal Value

Today (July 19) News: Apeiron Therapeutics announced that it has reached an agreement with Exscientia to transfer itsHighly Selective Oral CDK7 Inhibitor50% of the equity in GTAEXS617 was sold to Exscientia. Public information shows,GTAEXS617, developed through a collaboration between Apeiron Therapeutics and Exscientia, is currentlyCurrently in the ELUCIDATE Phase 1/2 clinical trial stage.

According to the agreement, Apeiron will receive a deal worth $30 million, including $10 million in cash, $10 million in Exscientia stock, and high single-digit royalties from the project's external licensing.Potential Value Exceeds $100 MillionIn addition, Exscientia will bear all the R&D expenses of the ongoing projects of 617.

Inhibiting CDK7 protein kinase offers various potential benefits, including transcriptional suppression, reduction of abnormal kinome activation, cell cycle inhibition, and modulation of estrogen receptor activity.This makes it a highly potential target for overcoming resistance to CDK4/6 inhibitors, which only target the cell cycle.。Apeiron Therapeutics press release stated,Based on the characteristics of the CDK7 signaling pathway and the molecular structure designed by AI, which can precisely control the degree/duration of target inhibition to maximize efficacy, 617 is expected to overcome the safety and efficacy limitations of approved therapies.

It is reported that ELUCIDATE is currently in the single-agent dose-escalation phase, with recruitment proceeding smoothly. Data is expected to be available in the second half of 2024. The study will transition to the combination therapy dose-escalation phase by the end of 2024 or early 2025, during which...First explore the effect of 617 in combination with Selective Estrogen Receptor Degraders (SERD) in HR+/HER2- breast cancer patients who have progressed after CDK4/6 treatment.。

Apeiron Therapeutics CEO Dr. Mingxi Li stated:"We are confident in the prospects of GTAEXS617 and believe that Exscientia has the best resources and capabilities to develop this project. GTAEXS617 will bring more treatment options and hope to cancer patients."This transaction enables us to focus our resources onOthers withPipeline with Significant Potential for "Synthetic Lethality"Above, including those about to enter clinical trialsMTA/PRMT5 InhibitorGTA182。”

Disclaimer:

The content of the article is for reference only and does not constitute investment advice. Investors who take actions based on this information bear their own risks. The article maintains a neutral stance on the statements and viewpoints presented, and does not provide any express or implied guarantees regarding the accuracy, reliability, or completeness of the content contained within. Readers are advised to use the information as a reference only and assume full responsibility for their actions. The various articles published by this official account focus on sharing; if there is any infringement, please contact us, and we will delete them.